Does the media prefer DSGN or KROS?

In the previous week, Design Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Design Therapeutics and 2 mentions for Keros Therapeutics. Design Therapeutics' average media sentiment score of 1.56 beat Keros Therapeutics' score of 0.94 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KROS or EVMN?

In the previous week, Evommune had 11 more articles in the media than Keros Therapeutics. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.94 beat Evommune's score of -0.53 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer PHAT or KROS?

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 0.94 beat Phathom Pharmaceuticals' score of 0.63 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ESPR or KROS?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Keros Therapeutics. Esperion Therapeutics' average media sentiment score of 1.42 beat Keros Therapeutics' score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, VOR or KROS?

Keros Therapeutics has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Keros Therapeutics $244.06M 0.87 $87.01M -$3.01 N/A

Does the media refer more to VOR or KROS?

In the previous week, Vor Biopharma had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Keros Therapeutics. Vor Biopharma's average media sentiment score of 0.94 equaled Keros Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Keros Therapeutics (KROS) Competitors

$10.70 -0.23 (-2.10%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$10.68 -0.01 (-0.14%)

As of 06/30/2026 06:32 PM Eastern

Compare

KROS vs. DSGN, EVMN, PHAT, ESPR, and VOR

Should you buy Keros Therapeutics stock or one of its competitors? MarketBeat compares Keros Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keros Therapeutics include Design Therapeutics (DSGN), Evommune (EVMN), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

How does Keros Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Design Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Design Therapeutics and 2 mentions for Keros Therapeutics. Design Therapeutics' average media sentiment score of 1.56 beat Keros Therapeutics' score of 0.94 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 14.03%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 90.65%. Given Keros Therapeutics' higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Design Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Design Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Keros Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A

Summary

Design Therapeutics and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Evommune?

Keros Therapeutics (NASDAQ:KROS) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

71.6% of Keros Therapeutics shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Keros Therapeutics currently has a consensus price target of $20.40, indicating a potential upside of 90.65%. Evommune has a consensus price target of $45.63, indicating a potential upside of 243.59%. Given Evommune's stronger consensus rating and higher probable upside, analysts clearly believe Evommune is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

Keros Therapeutics has higher revenue and earnings than Evommune. Keros Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A
Evommune	$13M	36.79	-$68.87M	-$9.50	N/A

In the previous week, Evommune had 11 more articles in the media than Keros Therapeutics. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.94 beat Evommune's score of -0.53 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Evommune has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Evommune's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Evommune	N/A	N/A	N/A

Summary

Evommune beats Keros Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Phathom Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 125.81%. Keros Therapeutics has a consensus target price of $20.40, suggesting a potential upside of 90.65%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Phathom Pharmaceuticals is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 0.94 beat Phathom Pharmaceuticals' score of 0.63 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Keros Therapeutics' net margin of -256.60%. Phathom Pharmaceuticals' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Keros Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.94	-$221.25M	-$2.12	N/A
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A

Summary

Phathom Pharmaceuticals beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Esperion Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Keros Therapeutics. Esperion Therapeutics' average media sentiment score of 1.42 beat Keros Therapeutics' score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Keros Therapeutics' net margin of -256.60%. Esperion Therapeutics' return on equity of -0.14% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 75.32%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 90.65%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Keros Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A

Summary

Esperion Therapeutics beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Vor Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A

Vor Biopharma has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Vor Biopharma's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Vor Biopharma currently has a consensus target price of $42.25, indicating a potential upside of 129.49%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 90.65%. Given Vor Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Vor Biopharma is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Vor Biopharma had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Keros Therapeutics. Vor Biopharma's average media sentiment score of 0.94 equaled Keros Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vor Biopharma beats Keros Therapeutics on 10 of the 12 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$216.32M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-3.55	20.90	27.25	24.87
Price / Sales	0.87	341.80	540.68	102.84
Price / Cash	2.41	143.77	48.53	58.59
Price / Book	0.69	8.75	11.01	6.54
Net Income	$87.01M	$23.81M	$3.57B	$336.70M
7 Day Performance	-2.10%	3.60%	2.31%	2.88%
1 Month Performance	-1.83%	3.72%	1.39%	0.64%
1 Year Performance	-19.79%	68.80%	36.71%	31.34%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.207 of 5 stars	$10.70 -2.1%	$20.40 +90.7%	-19.9%	$216.32M	$244.06M	N/A	100
DSGN Design Therapeutics	2.0467 of 5 stars	$13.44 -2.5%	$16.50 +22.8%	+329.4%	$860.66M	N/A	N/A	40	News Coverage Positive News
EVMN Evommune	2.23 of 5 stars	$24.00 +1.9%	$49.25 +105.2%	N/A	$848.58M	$10M	N/A	45	News Coverage Analyst Downgrade
PHAT Phathom Pharmaceuticals	2.0999 of 5 stars	$10.34 -2.5%	$24.50 +136.9%	+13.1%	$846.21M	$175.11M	N/A	110
ESPR Esperion Therapeutics	2.7145 of 5 stars	$3.15 flat	$5.54 +75.9%	+221.0%	$811.73M	$403.14M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. DSGN, EVMN, PHAT, ESPR, and VOR

How does Keros Therapeutics compare to Design Therapeutics?

Summary

How does Keros Therapeutics compare to Evommune?

Summary

How does Keros Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Esperion Therapeutics?

Summary

How does Keros Therapeutics compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. DSGN, EVMN, PHAT, ESPR, and VOR

How does Keros Therapeutics compare to Design Therapeutics?

Does the media prefer DSGN or KROS?

Do analysts rate DSGN or KROS?

Is DSGN or KROS more profitable?

Which has more risk and volatility, DSGN or KROS?

Do insiders and institutionals have more ownership in DSGN or KROS?

Which has preferable valuation and earnings, DSGN or KROS?

Summary

How does Keros Therapeutics compare to Evommune?

Do insiders & institutionals have more ownership in KROS or EVMN?

Do analysts rate KROS or EVMN?

Which has preferable earnings & valuation, KROS or EVMN?

Does the media favor KROS or EVMN?

Is KROS or EVMN more profitable?

Summary

How does Keros Therapeutics compare to Phathom Pharmaceuticals?

Do analysts prefer PHAT or KROS?

Does the media prefer PHAT or KROS?

Which has more volatility & risk, PHAT or KROS?

Do insiders & institutionals hold more shares of PHAT or KROS?

Is PHAT or KROS more profitable?

Which has higher valuation and earnings, PHAT or KROS?

Summary

How does Keros Therapeutics compare to Esperion Therapeutics?

Does the media prefer ESPR or KROS?

Do insiders & institutionals have more ownership in ESPR or KROS?

Which has more volatility & risk, ESPR or KROS?

Is ESPR or KROS more profitable?

Do analysts prefer ESPR or KROS?

Which has better earnings & valuation, ESPR or KROS?

Summary

How does Keros Therapeutics compare to Vor Biopharma?

Which has more volatility & risk, VOR or KROS?

Which has preferable valuation and earnings, VOR or KROS?

Is VOR or KROS more profitable?

Do analysts rate VOR or KROS?

Do institutionals and insiders have more ownership in VOR or KROS?

Does the media refer more to VOR or KROS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools